These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 10173136

  • 1. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G.
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [Abstract] [Full Text] [Related]

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE, Kleijnen J.
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [Abstract] [Full Text] [Related]

  • 3. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D.
    Sante; 2001 Nov; 11(3):155-60. PubMed ID: 11641078
    [Abstract] [Full Text] [Related]

  • 4. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N.
    Rand J Econ; 2002 Nov; 33(3):469-87. PubMed ID: 12585303
    [Abstract] [Full Text] [Related]

  • 5. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ, Romeis JC.
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [Abstract] [Full Text] [Related]

  • 6. [Risk sharing methods in middle income countries].
    Inotai A, Kaló Z.
    Acta Pharm Hung; 2012 Dec; 82(1):43-52. PubMed ID: 22570986
    [Abstract] [Full Text] [Related]

  • 7. The NCI All Ireland Cancer Conference.
    Johnston PG, Daly PA, Liu E.
    Oncologist; 1999 Dec; 4(4):275-277. PubMed ID: 10545862
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF, Mason AR.
    J Clin Oncol; 2007 Jan 10; 25(2):191-5. PubMed ID: 17210939
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The economics of pediatric formulation development for off-patent drugs.
    Milne CP, Bruss JB.
    Clin Ther; 2008 Nov 10; 30(11):2133-45. PubMed ID: 19108801
    [Abstract] [Full Text] [Related]

  • 17. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S, Maarse H, Versluis E, Light DW.
    J Health Polit Policy Law; 2009 Dec 10; 34(6):979-1010. PubMed ID: 20018988
    [Abstract] [Full Text] [Related]

  • 18. Access to orphan drugs in Europe: current and future issues.
    Michel M, Toumi M.
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb 10; 12(1):23-9. PubMed ID: 22280193
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A, Martin P.
    Stud Hist Philos Biol Biomed Sci; 2006 Sep 10; 37(3):583-601. PubMed ID: 16980196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.